Cutera (NASDAQ:CUTR) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Stock Performance

Shares of NASDAQ CUTR opened at $0.33 on Friday. The firm has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.87. The stock has a market cap of $6.62 million, a P/E ratio of -0.05 and a beta of 1.26. Cutera has a 52-week low of $0.28 and a 52-week high of $4.97.

Institutional Trading of Cutera

Several institutional investors have recently added to or reduced their stakes in CUTR. Squarepoint Ops LLC lifted its stake in shares of Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 70,870 shares during the period. Bank of Montreal Can lifted its stake in Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the period. Finally, Ground Swell Capital LLC bought a new position in shares of Cutera during the 2nd quarter worth approximately $37,000. 90.70% of the stock is currently owned by institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.